source
- FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancerRevolution Medicines received FDA approval for its oral RAS inhibitor daraxonrasib, branded as Rasonque, to treat patients with metastatic pancreatic adenocarcinoma who have already received prior…
- Hansoh says China’s biopharma is shifting from follower to frontrunner, now behind 30% of investigational drugsHansoh Pharmaceutical used its first‑half earnings release to claim that China’s innovative biopharma sector is moving from a follower role to a frontrunner position. The company highlighted that…